Related Experiment Video
Updated: Jun 12, 2025
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
Published on: January 19, 2024
Mupirocin for Skin Infection: Clinical Experience from China
Jing Sun1, Tracy Lu1, Yan Dang1
1Medical & Scientific Affairs, Haleon (Formerly GSK Consumer Healthcare), Shanghai, People's Republic of China.
Abstract:
Mupirocin, an antibiotic produced by Pseudomonas fluorescens, is mainly used for the topical treatment of various skin and soft tissue infections caused by Staphylococcus (including methicillin-resistant Staphylococcus aureus) and Streptococcus around the world for decades. Nevertheless, the clinical application scope of mupirocin varies in different countries due to differences in their medical policies, prescription types, and drug resistance. According to the experience of Chinese doctors in the past few years, mupirocin presented low drug resistance rates, and could be used as a treatment option for various primary infections and secondary infections, with antibacterial effects in a broad application. In this review, we summarized the experience of mupirocin used in the Chinese population and discussed its clinical value to provide novel insights and inspiration for physicians.
Insights
Mupirocin effectively treats skin infections caused by Staphylococcus and Streptococcus, showing low resistance rates in China. This review highlights its broad clinical value for physicians treating various infections.
Area of Science:
- Microbiology
- Pharmacology
- Dermatology
Background:
- Mupirocin, an antibiotic from Pseudomonas fluorescens, is globally used for topical treatment of skin infections.
- Its clinical use varies internationally due to differing medical policies and resistance patterns.
- Methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus are key targets.
Purpose of the Study:
- To review the clinical application and value of mupirocin in the Chinese population.
- To analyze mupirocin's efficacy and resistance rates based on Chinese medical experience.
- To provide insights for physicians regarding mupirocin's broad-spectrum antibacterial effects.
Main Methods:
- Literature review of mupirocin usage in China.
- Analysis of clinical data and physician experiences.
- Summary of reported resistance rates and treatment outcomes.
Main Results:
- Mupirocin demonstrates low drug resistance rates in the Chinese population.
- It is effective for treating both primary and secondary skin and soft tissue infections.
- Broad-spectrum antibacterial activity against key pathogens is observed.
Conclusions:
- Mupirocin remains a valuable topical antibiotic option in China.
- Its low resistance profile supports its continued use for various infections.
- Further insights into its clinical utility are provided for healthcare professionals.
